Abstract
Ninety-nine patients suspected of having pancreatic carcinoma were studied prospectively for carbohydrate tolerance. Thirty-two patients were proven subsequently to have pancreatic carcinoma; the remainder served as a control group. There was an increased incidence of carbohydrate intolerance in patients with pancreatic carcinoma compared to the control group. Insulin and C-peptide measurements during glucose tolerance tests suggest abnormal beta cell function and possibly insulin resistance as causes for this abnormality. Although factors related to malignancy in general could partly account for the results, a specific factor occurring in patients with pancreatic carcinoma must also be considered as it could serve as a marker for the early detection of this disease.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Zimmerman B: Editorial. Diabetes and gross lesions of the pancreas. J Clin Endocrinol Metab 14:481–483, 1954
Bell ET: Carcinoma of the pancreas II. The relation of carcinoma of the pancreas to diabetes mellitus Am J Pathol 33:499–523, 1957
Berkowitz D, Greenberg L, Glassman S: The intravenous tolbutamide test as a diagnostic aid in carcinoma of the pancreas. Am J Med Sci 243:150–154 (228–232), 1963
Birnbaum D, Kleeberg J: Carcinoma of the pancreas: A clinical study based on 84 cases. Ann Intern Med 48:1171–1184, 1958
Clark CG, Mitchell PEG: Diabetes mellitus and primary carcinoma of the pancreas. Br Med J 2:1259–1262, 1961
Glicksman AS, Rawson RW: Diabetes and altered carbohydrate metabolism in patients with cancer. Cancer 9:1227–1234, 1956
Green RC, Jr, Bagenstoss AH, Sprague RG: Diabetes mellitus in association with primary carcinoma of the pancreas. Diabetes 7:308–311, 1958
Karmody AJ, Kyle J: The association between carcinoma of the pancreas and diabetes mellitus. Br J Surg 56:362–364, 1969
Murphy R, Smith FH: Abnormal carbohydrate metabolism in pancreatic carcinoma. Med Clin North Am 47:397–405, 1963
Stein MW: Methods of Enzymatic Analysis. HV Bergmener (ed). Weinheim, Verlag Chemic, 1965, pp 117–123
Morgan CR, Lazarow A: Immunoassay of insulin: Two antibody system. Plasma levels of normal, subdiabetic and diabetic rats. Diabetes 12:115–126, 1963
Melani F, Rubenstein AH, Oyer PF, Steiner DF: Identification of proinsulin and C-peptide in human serum by a specific immunoassay. Proc Natl Acad Sci USA 67:148–155, 1970
Kuku SF, Zeidler A, Emmanouel DS, Katz AI, Rubenstein AH: Heterogeneity of plasma glucagon: Patterns in chronic renal failure and diabetes. J Clin Endocrinol Metab 42:173–176, 1976
Prout TE: The use of screening and diagnostic procedures: The oral glucose tolerance test. Diabetes Mellitus. KE Sussman, RJS Metz (eds). A.D.A., New York, 1975, pp 57–66
Siperstein MD: The glucose tolerance test: A pitfall in the diagnosis of diabetes mellitus. Adv Intern Med 20:297–323, 1975
Rubenstein AH, Steiner DF, Horwitz D, Mako M, Block MD, Starr JI, Kuzuya H, Melani J: CLinical significance of circulating proinsulin and C-peptide. Rec Prog Horm Res 33:435–475, 1977
Lisker SA, Brody JI, Beizer LH: Abnormal carbohydrate metabolism in patients with malignant blood dyscrasias. Am J Med Sci252:62–68 (282–288), 1966
Lipman RL, Rawkins P, Love T, Triebwasser J, Lecocq FR, Schnure JJ: Glucose intolerance during decreased physical activity in man. Diabetes 2:101–107, 1972
Pimstone B: Endocrine function in protein calorie malnutrition. Clin Endocrinol 5:79–95, 1976
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Schwartz, S.S., Zeidler, A., Moossa, A.R. et al. A prospective study of glucose tolerance, insulin, C-peptide, and glucagon responses in patients with pancreatic carcinoma. Digest Dis Sci 23, 1107–1114 (1978). https://doi.org/10.1007/BF01072886
Issue Date:
DOI: https://doi.org/10.1007/BF01072886